This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed outlook on top stocks. See full analyst rating changes & buy/sell recommendations for PBLS stock on Benzinga.read more...
Benzinga
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
Key PointsDirector Alan Sebulsky acquired 17,500 shares for $474,000, based on a weighted average purchase price of $27.06 per share...